Rocket Pharmaceuticals (RCKT) Notes Payables (2014 - 2021)

Rocket Pharmaceuticals (RCKT) reported Notes Payables of $5.1 million for Q2 2021, up 2.33% sequentially from $5.0 million in Q1 2021.

Rocket Pharmaceuticals (RCKT) Notes Payables (2014 - 2021) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 3 years of Notes Payables data on file, last reported at $5.1 million in Q2 2021.

For the quarter ending Q2 2021, Notes Payables changed N/A year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2021 stood at $5.1 million (changed N/A YoY), and the FY2020 full-year result was $4.9 million, changed N/A from the prior year.
Notes Payables improved to $5.1 million in Q2 2021, from $5.0 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $5.1 million in Q2 2021 to a low of $4.8 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Rocket Pharmaceuticals	357.93 Mn	357.93 Mn	-

Download Data